This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (33)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology, Other  • Oncology  • Drug Therapy  • Adverse Effects  • Gastrointestinal Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Jeffrey A. Allen, MD; Ashish Adlakha, MD; Peter R. Bergethon, MD

Arch Neurol. 2006;63:1475-1478.

Objective  To describe a patient with reversible posterior leukoencephalopathy syndrome following the administration of bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor.

Design  Case report/literature review.

Setting  University hospital.

Patient  A 52-year-old man receiving chemotherapy for stage IV rectal carcinoma.

Results  Clinical and radiographic evidence consistent with reversible posterior leukoencephalopathy syndrome was found following the administration of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy and bevacizumab.

Conclusions  Reversible posterior leukoencephalopathy syndrome following treatment with angiogenesis modulators can occur. In addition to raising clinical suspicion in appropriate patients, this report may yield clues to the pathophysiologic underpinnings of reversible posterior leukoencephalopathy syndrome.

Author Affiliations: Department of Neurology, Tufts–New England Medical Center, Boston, Mass. Dr Bergethon is now with the Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Understanding and managing the possible adverse effects associated with bevacizumab
Shord et al.
Am J Health Syst Pharm 2009;66:999-1013.
ABSTRACT | FULL TEXT  

Monoclonal Antibody Therapies and Neurologic Disorders
Novak et al.
Arch Neurol 2008;65:1162-1165.
ABSTRACT | FULL TEXT  

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
Mourad et al.
Ann Oncol 2008;19:927-934.
ABSTRACT | FULL TEXT  

Neuropsychiatric lupus and reversible posterior leucoencephalopathy syndrome: a challenging clinical dilemma
Mak et al.
Rheumatology (Oxford) 2008;47:256-262.
ABSTRACT | FULL TEXT  

Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature
Rajasekhar and George
The Oncologist 2007;12:1332-1335.
ABSTRACT | FULL TEXT  

Taming Glioblastoma: Targeting Angiogenesis
Wong and Brem
JCO 2007;25:4705-4706.
FULL TEXT  

Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome
Kapiteijn et al.
Ann Oncol 2007;18:1745-1747.
FULL TEXT  

Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy
van der Veldt et al.
Ann Oncol 2007;18:1747-1750.
FULL TEXT  

Dexamethasone-Induced Posterior Reversible Encephalopathy Syndrome
Irvin et al.
JCO 2007;25:2484-2486.
FULL TEXT